Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » Advocacy » Unicorn Foundation Speaks at Senate Inquiry

Unicorn Foundation Speaks at Senate Inquiry

  • October 11, 2015

On September 17 the Senate released their report from the inquiry with key recommendations that we hope are implemented.

Below is some of the key recommendations from the report released on 17 September, that the Unicorn Foundation endorses as a result of the Senate Inquiry. 

Key Recommendations

Recommendation 1 included:

  • that the Australian Government initiate a comprehensive review of the system for the registration and subsidisation of medicines. The review should examine:
  • all available pathways for registration and listing of new medicines including making provision for utilisations of assessments conducted by comparable overseas regulators; provision for clinicians and/or patient groups to apply for extension of existing registrations to additional indications, managed access programs and risk-sharing, and the adoption of more flexible evidential requirements
  • ensuring greater transparency throughout the assessment process
  • options for expanding post-market review of medicines
  • enhancing and formalising mechanisms for consumers and clinicians to play a more central and substantial role in the evaluation of new medicines and indications, including;      
  • consideration of options for expanding consumer and clinician representation on the PBAC;
  • enhancing existing avenues for stakeholder input, including the use of consumer and patient hearings

Recommendation 2 included:

  • the committee recommends that the Australian Government commission a review of current data collection mechanisms for cancer medicines, including identification of:
  • obstacles to the integration of exisiting databases and potential avenues for addressing these;
  • opportunities to incorporate data from post-market evaluations; and
  • avenues for capturing data relating to the off-label use of cancer medicines

Recommendation 3 included:

  • the committee recommends that the Australian Government establish a Steering Committee to examine the feasibility of establishing a national register of cancer medicines

We implore our patients and supporters to get behind these recommendations that urgent in the care of cancers and in particular rare cancers. 

Please write to your local member and ask them to endorse the recommendations that have come out of this historical inquiry click here for a list of all representatives.

For the Senate Inquiry report and recommendations download here

To view the day's proceedings click here or review the Unicorn Foundation submission on PDF format click here.

Share this post

Recent posts

VHL Awareness Month 2025

May 6, 2025

NET Patient Chris, from Ballarat, Raises Awareness of Neuroendocrine Cancer

May 5, 2025

Help Us Grow: Connect NECA with Corporate Partners to Make a Lasting Impact

April 29, 2025

Neuroendocrine Cancer Awareness Daily Mail 5 April 2025

April 5, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPrevious2015 INCA Patient Summit
NextFederal Health Department GrantNext

Related Posts

NET Patient Chris, from Ballarat, Raises Awareness of Neuroendocrine Cancer

NeuroEndocrine Cancer Australia (NECA) is proud to recognise the advocacy efforts of NET patient Chris Geljon, who has taken the time to raise awareness of

Help Us Grow: Connect NECA with Corporate Partners to Make a Lasting Impact

NeuroEndocrine Cancer Australia (NECA) is proud to be the voice for thousands of Australians living with Neuroendocrine Cancer (NETs). But to do more — reach

Parliament House representation for Federal Budget briefings

NECA attends the Treasurer’s Speech at Parliament House and then Medicines Australia Patient Organisation Brief at the Press Club on Wednesday 26 March 2025. The

VHL in the news March 2025

Read the Magazine copy here.

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin